We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune... CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. Show more
Ask ADVFN Intelligence (AI)
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference PR Newswire LA JOLLA, Calif., Nov. 21, 2024 LA JOLLA, Calif., Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc...
CalciMedica Announces Presentations at Upcoming Medical Meetings PR Newswire LA JOLLA, Calif., Nov. 20, 2024 Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™...
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., Nov. 13, 2024 Additional positive data, including a win ratio...
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer PR Newswire LA JOLLA, Calif., Nov. 7, 2024 LA JOLLA, Calif., Nov. 7, 2024 /PRNewswire/...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.33 | -9.76331360947 | 3.38 | 3.5 | 3.02 | 33558 | 3.22195682 | CS |
| 4 | -0.55 | -15.2777777778 | 3.6 | 3.6 | 3.02 | 50898 | 3.41874723 | CS |
| 12 | -1.81 | -37.2427983539 | 4.86 | 5.65 | 2.91 | 51806 | 3.87735972 | CS |
| 26 | -2.44 | -44.4444444444 | 5.49 | 5.97 | 2.91 | 47260 | 4.04651839 | CS |
| 52 | -0.98 | -24.317617866 | 4.03 | 8.38 | 2.68 | 33221 | 4.27448328 | CS |
| 156 | -13.33 | -81.3797313797 | 16.38 | 16.38 | 1.17 | 14491 | 4.12205662 | CS |
| 260 | -13.33 | -81.3797313797 | 16.38 | 16.38 | 1.17 | 10440 | 4.12205662 | CS |
TruckingAngler
4 weeks ago
heyitsmeagain
1 month ago
heyitsmeagain
1 month ago
TruckingAngler
1 month ago
TruckingAngler
10 months ago
TruckingAngler
1 year ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
